Your Health, We Care
As a new generation ROS1/NTRK inhibitor, repotrectinib has shown excellent efficacy in the treatment of ROS1+NSCLC.
In the TRIDENT-1 clinical trial, for ROS1+NSCLC patients treated with TKI, the progression free survival (mPFS) of repotrectinib was as long as 35.7 months, which exceeded the survival improvement achieved by previous first-line TKI treatments.
